FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2950931482> ?p ?o ?g. }

• W2950931482 abstract "1Seville, Seville, Spain Background Assessment of pain improvement during treatment for Rheumatoid Arthritis (RA) may be useful to clinical decision between providers and their patients (pts). Baricitinib (BARI) once daily, an oral, selective Janus Kinase (JAK)1/JAK2 inhibitor, reduced disease activity levels in Rheumatoid Arthritis (RA) patients (pts) with an inadequate response (IR) to methotrexate (MTX). Objectives To Evaluate the likelihood of achieving different levels of pain control with BARI 2 mg or 4 mg in patients with RA with inadequate response to traditional DMARDs or biological DMARDs. Methods Prospective observational registry of pts with RA who start treatment with BARI, in a third level Spanish Hospital (October 2017- June 2018). BARI 2 mg is started in patients with inadequate response to traditional DMARDs and BARI 4 mg in patients with inadequate response to biological DMARDs. The pts were assessment of pain was assessed with 0-100 mm visual analog scale (VAS) at each study visit. The likelihood of achieving >=25%, >=50% and >=70% pain VAS improvement through week 12 and analyze if there are significant differences between the group of patients with BARI 2 mg and BARI 4 mg (Mann-Whitney test). The statistical study was carried out with the SPSS15 computer package. Results We included 38 pts (28 women), mean age 52 ± 12 years. Pain VAS improvement for all patients, baseline pain and weeks 12. The frequency is the percentage of improvement with respect to the baseline. In BARI 2 mg group, 58% of pts (p75) have experienced a decrease greater than pain VAS improvement than baseline and in BARI 4 mg group, 55% of pts (p75) have experienced a decrease greater than pain VAS improvement than baseline. No statistically significant differences were found in the two treatment groups (BARI 2 mg and BARI 4 mg) (p 0.847). Conclusion Our results, in general, agree with what is published in the literature (RA treated with BARI reported greater improvements in pain control when compared to adalimumab or placebo, a post-hoc analysis of the Phase 3 RA-BEAM study). BARI treated pts reported significantly greater and more rapid reductions in pain severity as measured by the pain VAS, improvements were sustained 12 weeks, without finding differences in pts receiving BARI 2 mg or BARI 4 mg. Disclosure of Interests None declared" @default.
• W2950931482 created "2019-06-27" @default.
• W2950931482 creator A5000910912 @default.
• W2950931482 creator A5003611307 @default.
• W2950931482 creator A5021262915 @default.
• W2950931482 creator A5026813386 @default.
• W2950931482 creator A5032074360 @default.
• W2950931482 creator A5071719503 @default.
• W2950931482 creator A5073756101 @default.
• W2950931482 date "2019-05-27" @default.
• W2950931482 modified "2023-09-27" @default.
• W2950931482 title "AB0324 PAIN IMPROVEMENT IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH BARICITINIB: RESULTS OF A PROSPECTIVE STUDY" @default.
• W2950931482 doi "https://doi.org/10.1136/annrheumdis-2019-eular.5885" @default.
• W2950931482 hasPublicationYear "2019" @default.
• W2950931482 type Work @default.
• W2950931482 sameAs 2950931482 @default.
• W2950931482 citedByCount "0" @default.
• W2950931482 crossrefType "proceedings-article" @default.
• W2950931482 hasAuthorship W2950931482A5000910912 @default.
• W2950931482 hasAuthorship W2950931482A5003611307 @default.
• W2950931482 hasAuthorship W2950931482A5021262915 @default.
• W2950931482 hasAuthorship W2950931482A5026813386 @default.
• W2950931482 hasAuthorship W2950931482A5032074360 @default.
• W2950931482 hasAuthorship W2950931482A5071719503 @default.
• W2950931482 hasAuthorship W2950931482A5073756101 @default.
• W2950931482 hasBestOaLocation W29509314821 @default.
• W2950931482 hasConcept C126322002 @default.
• W2950931482 hasConcept C14184104 @default.
• W2950931482 hasConcept C1862650 @default.
• W2950931482 hasConcept C188816634 @default.
• W2950931482 hasConcept C23131810 @default.
• W2950931482 hasConcept C2777077863 @default.
• W2950931482 hasConcept C2777575956 @default.
• W2950931482 hasConcept C2781059491 @default.
• W2950931482 hasConcept C71924100 @default.
• W2950931482 hasConceptScore W2950931482C126322002 @default.
• W2950931482 hasConceptScore W2950931482C14184104 @default.
• W2950931482 hasConceptScore W2950931482C1862650 @default.
• W2950931482 hasConceptScore W2950931482C188816634 @default.
• W2950931482 hasConceptScore W2950931482C23131810 @default.
• W2950931482 hasConceptScore W2950931482C2777077863 @default.
• W2950931482 hasConceptScore W2950931482C2777575956 @default.
• W2950931482 hasConceptScore W2950931482C2781059491 @default.
• W2950931482 hasConceptScore W2950931482C71924100 @default.
• W2950931482 hasLocation W29509314821 @default.
• W2950931482 hasOpenAccess W2950931482 @default.
• W2950931482 hasPrimaryLocation W29509314821 @default.
• W2950931482 hasRelatedWork W2144030527 @default.
• W2950931482 hasRelatedWork W2263807238 @default.
• W2950931482 hasRelatedWork W2264570451 @default.
• W2950931482 hasRelatedWork W2278284019 @default.
• W2950931482 hasRelatedWork W2300537080 @default.
• W2950931482 hasRelatedWork W2316010001 @default.
• W2950931482 hasRelatedWork W2367762172 @default.
• W2950931482 hasRelatedWork W2408847739 @default.
• W2950931482 hasRelatedWork W2411380196 @default.
• W2950931482 hasRelatedWork W2551902274 @default.
• W2950931482 hasRelatedWork W2586554770 @default.
• W2950931482 hasRelatedWork W2754749197 @default.
• W2950931482 hasRelatedWork W2910996710 @default.
• W2950931482 hasRelatedWork W3087386396 @default.
• W2950931482 hasRelatedWork W3088386202 @default.
• W2950931482 hasRelatedWork W3109024239 @default.
• W2950931482 hasRelatedWork W3124558507 @default.
• W2950931482 hasRelatedWork W3186062956 @default.
• W2950931482 hasRelatedWork W73315721 @default.
• W2950931482 hasRelatedWork W3146091660 @default.
• W2950931482 isParatext "false" @default.
• W2950931482 isRetracted "false" @default.
• W2950931482 magId "2950931482" @default.
• W2950931482 workType "article" @default.